Tag Archives: Oxford

The Brexit Mess Planned All Along To Thwart The Will Of The People – David Icke

What are we to make of these Rt Honourable Oxbridge graduates, Tony Blair, David Cameron and Theresa May?

“May later attended the University of Oxford”

“he (Blair) enrolled for university at St John’s College, Oxford, reading Jurisprudence for three years”

“Cameron began his Bachelor of Arts course in Philosophy, Politics and Economics (PPE) at Brasenose College, Oxford”

They are  not stupid people, so this mess is intentional. I agree with David Icke totally on this. To engineer a Brexit deal worse that remaining in the EU takes some collusion by both parties – May and the EU.

Based on their compulsive lying in support of the EU we can be sure they serve their “hidden hand” masters, They are willing treacherous accomplices.

We can now add another lying treacherous scumbag to this group, privy council oath taker Jeremy Corbyn.

We can take note in December 2018 that 3 recent Prime Ministers being the recipients  of the best (once free) University education Britain has to offer are compliant before the TTIP/TPP corporatist pile of excrement called the European Union.

Advertisements

RT: Genetically engineered mosquitoes battle Zika virus in Brazil

https://www.rt.com/news/329504-gm-mosquito-zika-virus-brazil/

The ‘Friendly Aedes aegypti Project’ conducted by the company’s subsidiary Oxitec aims to tackle the virus spread in the city of Piracicaba, based on the success of previous preventative measures introduced across Central and South America.

“As the principal source for the fastest growing vector-borne infection in the world in Dengue Fever, as well as the increasingly challenging Zika virus, controlling the Aedes aegypti population provides the best defense against these serious diseases for which there are no cures,” said Oxitec CEO Hadyn Parry.
…Oxitec is initiating a new mosquito production facility in Piracicaba that will have capacity to protect over 300,000 people,”

…Oxitec’s previous trials on mosquito population began in April 2015 after Brazil’s National Biosafety Committee (CTNBio) gave the green light for the UK company to release the insects into the wild.

“By the end of the calendar year, results had already indicated a reduction in wild mosquito larvae by 82 percent. Oxitec’s efficacy trials across Brazil, Panama and the Cayman Islands all resulted in a greater than 90 percent suppression of the wild Ae. aegypti mosquito population – an unprecedented level of control,” the statement said.

Marketwatch Oxitec aricle

“Intrexon Corporation [http://www.dna.com/] , a leader in synthetic biology, today announced its subsidiary Oxitec and Piracicaba City Hall have expanded the ‘Friendly Aedes aegypti Project’ in Piracicaba, Brazil following strong results for controlling the Ae. aegypti mosquito population, the primary vector for dengue, chikungunya and Zika virus outbreaks around the world

Samuel Broder, M.D., SVP and Head of Intrexon’s Health Sector commented, “As a vector that transmits a number of serious diseases, the Aedes aegypti mosquito poses a major threat to public health and the economic welfare of nations. Brazil has been hard hit by dengue and the situation there has been aggravated by the recent introduction of Zika virus infections leading to a startling increase in the number of children being born with microcephaly.” Dr. Broder continued, “Through the responsible engineering of biology, we demonstrate a new paradigm of species-specific vector control resulting in dramatic reductions of dangerous mosquitoes, without persistence or harm to the ecosystem, representing a major scientific, environmental and clinical advance.”

 

Aedes aegypti OX513A

http://www.oxitec.com/health/our-products/aedes-agypti-ox513a/
Product profile
OX513A is a bisex RIDL strain. Males are released to mate with wild females. The progeny of such matings die as late larvae or pupae. Continual releases of sufficient numbers of RIDL males will reduce the target population to below the level needed to transmit disease. The late lethality means that RIDL larvae compete with wild-type larvae for resources,adding to the overall effectiveness of control. Before release, male and female pupae are separated mechanically, exploiting the fact that they are naturally significantly different in size. The strain contains the DsRed marker which is clearly visible in larvae, a useful tool for quality control in production and effective monitoring in the field. OX513A is available in Asian and Latin American genetic backgrounds.

Status
OX513A has regulatory approvals for import and contained testing in Brazil, Cayman Islands, France, India, Malaysia, Singapore, Thailand, USA and Vietnam. Open field trials have taken place in both Grand Cayman and Malaysia, and are currently also underway in Brazil.

Oxitec (GM Mosqitoes) – Our Team

Oxitec Ltd. was founded in 2002 and is based in Oxford, United Kingdom. As of September 8, 2015, Oxitec Ltd. operates as a subsidiary of Intrexon Corporation.

http://www.oxitec.com/who-we-are/our-team/

Hadyn Parry, Chief Executive Officer

Hadyn ParryHadyn has an extensive background in the Life Science sector. During his fifteen-year career at Zeneca/Syngenta he held various positions, including General Manager of Zeneca Plant Sciences and European Director and Global Head of R&D for Advanta, one of the world’s largest seed companies. More recently he was CEO of MNL Pharmaceuticals, a company that was focused on pioneering a novel approach in immunology. Hadyn is also Chairman of Help For Heroes, a charity founded in 2007 to support wounded British soldiers.

Simon Warner, Chief Scientific Officer

Simon WarnerSimon has eighteen years of global commercial experience in biotechnology R&D in various roles at Syngenta in the United Kingdom and the United States, leading collaborative programs and delivering biotechnology products in crops for feed and fuel. Additionally, whilst at Syngenta he also worked as the R&D lead on technology acquisition on various agreements. Immediately prior to joining Oxitec, he was Senior Director of Research and Development Programs at Sapphire Energy, a start-up making algae based fuel, based in San Diego, California. Simon has a BSc in biochemistry from UCL and PhD in plant molecular biology from the University of Leicester.

Bill Fleming, Chief Financial Officer

Bill Fleming Bill joins us from Bayer Healthcare having held senior finance positions in Europe and the USA. He has a law degree from Cambridge University and is a qualified ACMA. Previously, Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics.

Camilla Beech, Regulatory Affairs Manager

Camilla BeechCamilla has extensive international experience in the regulation of biotechnology products and crops. She obtained commercial food approval in the UK for the first GM crop in Europe, and obtained registrations for numerous biotechnology crops in Africa, Asia and the Americas. She advised the Humanitarian Board for Golden Rice on regulatory matters (1997 to 2004), and was a member of both US (BIO) and European Inter-industry groups (EUROPABIO) on The Cartagena Biosafety Protocol, Convention on Biological Diversity and Plant made Pharmaceuticals. Her most recent post was International Regulatory Manager for Syngenta Biotechnology Inc., based in San Diego, California.

Glen Slade, Head of Business Development

Glen SladeGlen has worked in agribusiness since 1998 when he joined Zeneca Agrochemicals as Head of Strategy. There he championed the role of biotechnology in integrated crop solutions, leading to the merger that formed Syngenta. He then worked in independent consulting roles addressing high profile marketing and strategy projects for Syngenta, Arysta and other agribusiness firms. In parallel to this work, Glen set up and ran two IT-related companies. He has a degree from Cambridge University and an MBA from Insead.